Ac-AKY-2519 not checked

Aktis Oncology, Inc. · Cu-AKY-2519

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Prostate Cancer (2 trials), mCRPC (Metastatic Castration-resistant Prostate Cancer) (2 trials), B7H3 (2 trials), Castration Resistant Metastatic Prostate Cancer, mCRPC, NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC and 6 more
Main trialPhase 1
“This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with metastatic castration-resistant prostate cancer (mCRPC) with and without prior exposure to 177Lu-PSMA-617 (PLUVICTO™).”In the company’s words, NCT07581184 on ClinicalTrials.gov
Other names
Cu-AKY-2519

Other drugs for Prostate Cancer

All 194 drugs for Prostate Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Dec 2027 A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1Recruiting Dec 2028 A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ac-AKY-2519

Following is part of Solo: you see every change to Ac-AKY-2519 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in